Switch theme
Sign up to access all valuation multiples
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
2012
166
LTM Revenue $25.1M
LTM EBITDA -$18.6M
$45.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ProQR Therapeutics has a last 12-month revenue (LTM) of $25.1M and a last 12-month EBITDA of -$18.6M.
In the most recent fiscal year, ProQR Therapeutics achieved revenue of $18.9M and an EBITDA of -$24.1M.
ProQR Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ProQR Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $25.1M | XXX | $18.9M | XXX | XXX | XXX |
| Gross Profit | $25.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$18.6M | XXX | -$24.1M | XXX | XXX | XXX |
| EBITDA Margin | -74% | XXX | -128% | XXX | XXX | XXX |
| EBIT | -$42.9M | XXX | -$30.5M | XXX | XXX | XXX |
| EBIT Margin | -171% | XXX | -161% | XXX | XXX | XXX |
| Net Profit | -$39.2M | XXX | -$27.8M | XXX | XXX | XXX |
| Net Margin | -156% | XXX | -147% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ProQR Therapeutics's stock price is $2.
ProQR Therapeutics has current market cap of $175M, and EV of $45.1M.
See ProQR Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45.1M | $175M | XXX | XXX | XXX | XXX | $-0.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ProQR Therapeutics has market cap of $175M and EV of $45.1M.
ProQR Therapeutics's trades at 2.4x EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate ProQR Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ProQR Therapeutics has a P/E ratio of -5.0x.
See valuation multiples for ProQR Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $175M | XXX | $175M | XXX | XXX | XXX |
| EV (current) | $45.1M | XXX | $45.1M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.0x | XXX | -6.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProQR Therapeutics's last 12 month revenue growth is -1%
ProQR Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
ProQR Therapeutics's rule of 40 is -371% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ProQR Therapeutics's rule of X is -77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ProQR Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Margin | -74% | XXX | -128% | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -371% | XXX | -129% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -77% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 192% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 261% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ProQR Therapeutics acquired XXX companies to date.
Last acquisition by ProQR Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . ProQR Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ProQR Therapeutics founded? | ProQR Therapeutics was founded in 2012. |
| Where is ProQR Therapeutics headquartered? | ProQR Therapeutics is headquartered in United States of America. |
| How many employees does ProQR Therapeutics have? | As of today, ProQR Therapeutics has 166 employees. |
| Who is the CEO of ProQR Therapeutics? | ProQR Therapeutics's CEO is Mr. Daniel de Boer. |
| Is ProQR Therapeutics publicy listed? | Yes, ProQR Therapeutics is a public company listed on NAS. |
| What is the stock symbol of ProQR Therapeutics? | ProQR Therapeutics trades under PRQR ticker. |
| When did ProQR Therapeutics go public? | ProQR Therapeutics went public in 2014. |
| Who are competitors of ProQR Therapeutics? | Similar companies to ProQR Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ProQR Therapeutics? | ProQR Therapeutics's current market cap is $175M |
| What is the current revenue of ProQR Therapeutics? | ProQR Therapeutics's last 12 months revenue is $25.1M. |
| What is the current revenue growth of ProQR Therapeutics? | ProQR Therapeutics revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of ProQR Therapeutics? | Current revenue multiple of ProQR Therapeutics is 2.0x. |
| Is ProQR Therapeutics profitable? | Yes, ProQR Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ProQR Therapeutics? | ProQR Therapeutics's last 12 months EBITDA is -$18.6M. |
| What is ProQR Therapeutics's EBITDA margin? | ProQR Therapeutics's last 12 months EBITDA margin is -74%. |
| What is the current EV/EBITDA multiple of ProQR Therapeutics? | Current EBITDA multiple of ProQR Therapeutics is -2.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
